Mitogen-Activated Protein Kinase–Activated Protein Kinase 2 in Angiotensin II–Induced Inflammation and Hypertension

Regulation of Oxidative Stress

Talin Ebrahimian, Melissa Wei Li, Catherine A. Lemarié, Stefania M.C. Simeone, Patrick J. Pagano, Matthias Gaestel, Pierre Paradis, Sven Wassmann, Ernesto L. Schiffrin

Abstract—Vascular oxidative stress and inflammation play an important role in angiotensin II–induced hypertension, and mitogen-activated protein kinases participate in these processes. We questioned whether mitogen-activated protein kinase–activated protein kinase 2 (MK2), a downstream target of p38 mitogen–activated protein kinase, is involved in angiotensin II–induced vascular responses. In vivo experiments were performed in wild-type and Mk2 knockout mice infused intravenously with angiotensin II. Angiotensin II induced a 30 mm Hg increase in mean blood pressure in wild-type that was delayed in Mk2 knockout mice. Angiotensin II increased superoxide production and vascular cell adhesion molecule-1 in blood vessels of wild-type but not in Mk2 knockout mice. Mk2 knockdown by small interfering RNA in mouse mesenteric vascular smooth muscle cells caused a 42% reduction in Mk2 protein and blunted the angiotensin II–induced 40% increase of MK2 expression. Mk2 knockdown blunted angiotensin II–induced doubling of intracellular adhesion molecule-1 expression, 2.4-fold increase of nuclear p65, and 1.4-fold increase in Ets-1. Mk2 knockdown abrogated the angiotensin II–induced 4.7-fold and 1.3-fold increase of monocyte chemoattractant protein-1 mRNA and protein. Angiotensin II enhanced reactive oxygen species levels (by 29%) and nicotinamide adenine dinucleotide phosphate oxidase activity (by 48%), both abolished by Mk2 knockdown. Reduction of Mk2 blocked angiotensin II–induced p47phox translocation to the membrane, associated with a 53% enhanced catalase expression. Angiotensin II–induced increase of MK2 was prevented by the nicotinamide adenine dinucleotide phosphate oxidase inhibitor Nox2ds-tat. Mk2 small interfering RNA prevented the angiotensin II–induced 30% increase of proliferation. In conclusion, MK2 plays a critical role in angiotensin II signaling, leading to hypertension, oxidative stress via activation of p47phox and inhibition of antioxidants, and vascular inflammation and proliferation. (Hypertension. 2011; 57:00-00.)

Key Words: MK2 ■ angiotensin II ■ oxidative stress ■ vascular inflammation ■ hypertension ■ arterial

Vascular wall inflammation plays a key role in the pathogenesis of hypertension, atherosclerosis, and other forms of cardiovascular disease. Angiotensin II (Ang II) induces vascular injury by modulating release of inflammatory chemokines such as monocyte chemoattractant protein-1 (MCP-1)1 and the nuclear action of proinflammatory transcription factors such as nuclear factor-κB (NF-κB). The latter, in turn, regulates expression of vascular cell adhesion molecule-1 (VCAM-1)2 and intracellular adhesion molecule-1 (ICAM-1). These events induce inflammation within the vascular wall, deposition of extracellular matrix and hypertrophy or hyperplasia of vascular smooth muscle cells (VSMCs). Ang II actions in the vascular wall are mediated in large measure through increase in the generation of reactive oxygen species (ROS).3 The major source of ROS in the vessel wall is reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase.4 Upon stimulation by Ang II or other agents, the cytosolic subunits are translocated to the membrane and assemble with the membrane subunits to form the active NADPH oxidase capable of producing superoxide anion (·O2−). Redox-sensitive pathways are important in Ang II–stimulated growth and differentiation of cells, probably through activation of mitogen-activated protein kinases (MAPKs).5

p38 MAPK is markedly activated in cardiovascular cells by a variety of stimuli, including Ang II, and typically mediates apoptosis and inflammatory responses. Ang II rapidly stimulates the phosphorylation of p38 MAPK in cultured VSMCs6 as well as in cardiac and vascular tissues.7 Some in vitro studies suggest that Ang II–induced activation

Received July 21, 2010; first decision August 16, 2010; revision accepted November 10, 2010.

From the Lady Davis Institute for Medical Research (T.E., M.W., C.A.L., S.M.C.S., P.P., S.W., E.L.S.) and Department of Medicine (S.W., E.L.W.), Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montréal, Québec, Canada; Department of Pharmacology and Chemical Biology (P.J.P.), University of Pittsburgh School of Medicine, Pittsburgh, PA; and Institute of Biochemistry (M.G.), Medical School of Hannover, Germany.

Correspondence to Ernesto L. Schiffrin, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, 3755 Côte-Ste-Catherine Rd, B-127, Montréal, Québec, Canada H3T 1E2. E-mail ernesto.schiffrin@mcmill.ca

Hypertension is available at http://hyper.ahajournals.org DOI: 10.1161/HYPERTENSIONAHA.110.159889
of NADPH oxidase results in upregulation of p38 MAPK.\textsuperscript{8,9} In addition, p38 MAPK plays an important role in endothelial inflammation and dysfunction associated with salt-sensitive hypertension.\textsuperscript{10} Treatment with SB202190, a p38 MAPK inhibitor, resulted in marked reductions in blood pressure in a diabetic rat model, which underlines the role of p38 MAPK in hemodynamic control.\textsuperscript{11} Upregulation of p38 MAPK induces early response gene expression and cell growth.\textsuperscript{12,13} Finally, in VSMCs from spontaneously hypertensive rat, p38 MAPK has been shown to influence Ang II–induced collagen production.\textsuperscript{14}

p38 MAPK activates many protein kinases, such as MAPK-activated protein kinase 2 (MK2).\textsuperscript{15} MK3, MAPK-interacting kinases 1\textsuperscript{16} and 2, and p38-regulated/activated protein.\textsuperscript{17} Phosphorylation of MK2 by p38 MAPK unmasks a nuclear export signal in the C-terminal part of the molecule.\textsuperscript{18,19} Several substrates have been described for MK2, including mRNA-binding proteins such as tristetraproline, transcription factors such as heat shock protein-1, proteins interacting with the cytoskeleton such as heat shock protein-25, as well as regulators of the cell cycle and apoptosis such as Cdc25B/C.\textsuperscript{20–24} Interaction of p38 MAPK with the preexisting complex of heat shock protein-27 and Akt is mediated by MK2.\textsuperscript{25} MK3, an isoform of MK2, was shown by Ronkina et al using a gene targeting approach to be coexpressed with MK2 in cells and tissues and to share similar physiological functions.\textsuperscript{26} More recently, MK2 knockout (KO) mice were demonstrated to be more resistant to lipopolysaccharide-induced endotoxemic shock as a consequence of a reduction of tumor necrosis factor–α production.\textsuperscript{27}

In the present study, we investigated in vivo and in vitro whether MK2, one of the downstream targets of p38 MAPK, is involved in the pathway that mediates Ang II–induced inflammation, oxidative stress, and proliferation in VSMCs from mesenteric arteries, and in Ang II–induced hypertension. In vivo experiments were performed examining the effects of Ang II infusion into MK2 KO mice. In vitro, Ang II action was tested on VSMCs in which MK2 knockdown was achieved using small interfering RNA (siRNA).

**Methods**

An expanded Methods section can be found in an online data supplement available at http://hyper.ahajournals.org.

**Animals and Blood Pressure Determination**

Ten-week-old male C57BL/6 mice (Harlan Laboratories; Indianapolis, IN) were killed humanely by exsanguination under isoflurane anesthesia. Mesenteric arteries were dissected and used for the isolation of VSMCs. Fourteen- to 17-week-old male wild-type (WT) littermates were anesthetized with isoflurane, surgically instrumented with PA-C10 radiotransmitters as recommended by the manufacturer (Data Sciences International; St. Paul, MN), allowed to recover for 10 days, and then blood pressure was determined every 5 minutes for 10 s for 3 consecutive days. Thereafter, mice were infused with Ang II (400 ng/kg/min; Calbiochem; EMD Biosciences Inc.) or vehicle (Veh) using Alzet osmotic mini-pumps (DURECT Corp.) for 14 days. Blood pressure was determined as above during the 2-week treatment successfully in 5 WT + Veh, 3 WT + Ang II, 3 MK2 + Veh, and 4 MK2 + Ang II. At the end of the experiment, mice were killed as above, and the mesenteric vascular bed and aorta were dissected, frozen, and stored at −80°C for VCAM-1 and superoxide determination.

**Cell Culture and Stimulation**

VSMCs were isolated from mesenteric arteries as described previously\textsuperscript{28} and were used after 3 to 6 passages. They were transfected with siRNA (5 nmol/L; Qiagen; Mississauga, ON, Canada) targeting MK2 (siMK2) or luciferase used as a negative control for 30 hours, or with a control fluorescein isothiocyanate (FITC)–coupled siRNA (10 μmol/L; Santa Cruz Biotechnology; Santa Cruz, CA) used to determine the efficiency of transfection. VSMCs were serum starved for 18 hours and treated with vehicle or Ang II (100 nmol/L) for 10 minutes to 24 hours, depending on the experiments. In some experiments, cells were also pre-exposed for 30 minutes to 10 μmol/L Nox2ds-tat (NADPH oxidase inhibitor) or to scrambled peptide used as negative control before stimulation with Ang II.\textsuperscript{29} For the efficiency of transfection after being transfected with FITC-coupled siRNA, VSMCs were stained with 4',6-diamidino-2-phenylindole (Sigma Chemicals). Fluorescence was visualized with a DM2000 microscope with an FITC filter (488 nm; Leica Microsystems).

**Nuclear Extract Preparation**

VSMC nuclear extracts were prepared as described previously\textsuperscript{30} (details in the online supplement).

**Western Blotting**

Total or fractioned proteins (15 to 20 μg) were extracted from VSMCs, separated by SDS-PAGE, transferred to nitrocellulose membranes, and incubated overnight at 4°C with antibodies (1:1000) against the following: MK2, p38 MAPK, and NF-κB p65 subunit (from Cell Signaling Technology), and ICAM-1, VCAM-1, Ets-1, and p47phox (from Santa Cruz Biotechnology). After incubation with secondary antibodies, signals were revealed by chemiluminescence (SuperSignal West Pico chemiluminescent signal; Thermo Scientific), with the Molecular Imager Chemidoc XRS system (Bio-Rad), and quantified by densitometry using Quantity One software (Bio-Rad). Membranes were subsequently stripped and reprobed with anti–β-actin antibody (Sigma Chemicals) to verify equal loading. VCAM-1 was also determined in protein extracts of mesenteric arteries from MK2 KO and WT mice.

**Quantitative RT-PCR**

MCP-1 mRNA expression levels were determined by quantitative real-time PCR. RNA was extracted from VSMCs using the TRIzol reagent (Invitrogen). One microgram of total RNA was reversed transcribed with a Quantitect RT kit (Qiagen). Quantitative real-time PCR was performed using a Quantitect SYBR Green PCR Kit (Qiagen) with the Mx3005P real-time PCR cycler (Stratagene). Quantitative real-time PCR results were normalized with ribosomal protein S16 and expressed as fold change of negative-control siRNA-treated samples. Primers were designed using Primer3\textsuperscript{31} and are presented in the online data supplement.

**MCP-1 Assay**

MCP-1 levels were measured in the supernatant of VSMCs using a simplex microbead-based immunoassay kit on a Bio-Plex 200 (Bio-Rad) according to the manufacturer protocol.

**ROS Levels**

Intracellular ROS levels were evaluated using 5- (and 6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate, acetyl–ester mixed isomers (CM-H₂DCFDA; Invitrogen), a chloromethyl derivative of dichlorodihydrofluorescein diacetate that becomes fluorescent when oxidized. Dihydroethidium (DHE) was used to evaluate in situ production of superoxide (O₂⁻)\textsuperscript{32} (online supplement).

**NADPH Oxidase Activity**

The lucigenin-enhanced chemiluminescence assay was used to determine NADPH oxidase activity in VSMC homogenates as described previously\textsuperscript{33} VSMCs were transfected with siMK2 or
siRNA targeting luciferase, serum starved, and stimulated or not with Ang II for 5 minutes as above (online supplement).

**Proliferation Assay**

Ang II–stimulated DNA synthesis was determined by measuring incorporation of [3H]thymidine into DNA (online supplement).

**Statistical Analysis**

Experiments were repeated 3 to 6 times in duplicate. Results are presented as means ± SEM and were compared by analysis of variance followed by a Student Newman–Keuls post hoc test. *P* < 0.05 was considered significant.

**Results**

**Mk2 Deletion Delays and Blunts the Ang II–Induced Rise in Mean Blood Pressure**

To establish whether MK2 participates in Ang II–induced blood pressure rise in vivo, we measured mean blood pressure (MBP) by radiotelemetry in WT and Mk2 KO mice infused or not with Ang II for 14 days. No significant difference in day and night MBP was observed between Mk2 KO and WT mice at baseline and during the 14-day infusion with the vehicle (Figure 1). Ang II caused a 30- to 35-mm Hg increase in day and night MBP from day 2, which was maintained up to the end of the protocol in WT mice. Mk2 deletion delayed and blunted the rise in day and night MBP, respectively. Day MBP of Ang II–infused Mk2 KO mice increased significantly only at day 11 to day 14, whereas night MBP only tended to increase during the last few days of the protocol.

**Mk2 KO Reduces Ang II–Induced Vascular Superoxide Generation**

Superoxide ~$\cdot\text{O}_2$~ production was evaluated by DHE fluorescence in aorta sections of WT and Mk2 KO mice infused or not with Ang II for 14 days. Basal production of ~$\cdot\text{O}_2$~ was significantly enhanced by Mk2 deletion (Figure 2A). Ang II increased ~$\cdot\text{O}_2$~ production in both WT and Mk2 KO mice, but the increase was significantly blunted in Mk2 KO mice.

**Figure 1.** Mk2 deletion delays and blunts, respectively, the Ang II–induced day and night blood pressure rise in mice. MBP was determined by radiotelemetry in WT and Mk2 KO mice at baseline and during the infusion with vehicle (Veh) or Ang II (400 ng/kg/min) for 14 days. The day (6 AM to 8 PM) and night (8 PM to 6 AM) average MBPs are presented. Results are means ± SEM; *P* < 0.05 and **P* < 0.01 vs respective Veh, with n = 5 for WT + Veh, n = 3 for WT + Ang II, n = 3 for Mk2 + Veh, and n = 4 for Mk2 + Ang II.

**Figure 2.** Absence of MK2 prevents Ang II–induced superoxide and proinflammatory VCAM-1 production. In situ detection of superoxide generation in the aorta using DHE staining (A) and mesenteric artery protein level of VCAM-1 using Western blot (B) were determined in WT and Mk2 KO mice infused with vehicle (Veh) or Ang II (400 ng/kg/min) for 14 days. Representative Western blots of VCAM-1 and bar graphs representing VCAM-1 expression in different conditions are presented. Results are means ± SEM; n = 3 to 4; *P* < 0.05 vs respective WT + Veh.
production in WT mice, whereas this change was blunted in Mk2 KO mice.

**Mk2 Deletion Blunts Ang II–Induced Inflammatory Responses**

The levels of the proinflammatory molecule VCAM-1 were determined in mesenteric arteries of WT and Mk2 KO mice infused or not with Ang II for 14 days. Basal levels of VCAM-1 were increased 1.7-fold in Mk2 KO mice compared with WT mice (Figure 2B). Ang II infusion increased 1.4-fold the levels of VCAM-1 in WT mice and had no effect in Mk2 KO mice.

**Ang II Upregulates p38 MAPK and MK2**

Ang II increased p38 MAPK phosphorylation by 45% (Figure 3A) as well as MK2 phosphorylation and total expression in VSMCs by 29% and 39%, respectively (Figure 3B and 3D). For gene silencing experiments, the efficiency of VSMCs siRNA transfection was determined using a control FITC-siRNA. We observed an efficiency of 56% (Figure 3A) as well as MK2 phosphorylation and total expression in different conditions are depicted. Results are means±SEM; n=4 to 8; *P<0.05 vs Veh for A and B and vs siLuc+Veh for D, and †P<0.01 vs siLuc+Ang II for D.

**MK2 Is Involved in Ang II–Induced Increase of ICAM-1, NF-κB, Ets-1, and MCP-1**

VSMC Mk2 knockdown did not significantly alter protein levels of ICAM-1, VCAM-1, and Ets-1, but resulted in a1.5-fold increase of the nuclear level of the p65 subunit of NF-κB (Figure 4). Ang II increased ICAM-1 and nuclear p65 2-fold and Ets-1 1.4-fold without altering the levels of VCAM-1. siMK2 blunted these Ang II responses. siMK2 did not alter the basal expression of MCP-1, but abrogated the Ang II–induced 4.7- and 1.3-fold increase of MCP-1 at mRNA and protein levels, respectively (Figure 5). These results demonstrate the involvement of MK2 activation in some of Ang II–induced inflammatory pathways.

MK2 Mediates Ang II–Induced ROS Generation Via NADPH Oxidase

Intracellular ROS levels and in situ production of ·O2− were evaluated respectively in VSMCs by dichlorodihydrofluorescein diacetate and by DHE fluorescence. Mk2 knockdown did not affect the basal levels of intracellular ROS or generation of ·O2− in VSMCs (Figure 6A and 6B). Ang II increased intracellular ROS levels (by 29%) and production of ·O2− revealed by DHE staining in VSMCs, both abrogated by Mk2 knockdown. Ang II increased NADPH oxidase activity (48%), the main vascular source of ·O2− (Figure 6C). Mk2 knockdown abolished the increase in NADPH oxidase activity induced by Ang II without altering basal levels. These results suggest that Ang II–induced NADPH oxidase activation involves Mk2.

**Ang II/MK2–Induced NADPH Oxidase Involves p47phox Translocation**

To further understand the molecular pathways of activation of NADPH oxidase by Mk2, we examined the translocation of p47phox, one of the main cytosolic subunits of NADPH oxidase, the translocation of which from the cytosol to the membrane is essential for the assembling of the active NADPH oxidase in the cell membrane. Ang II increased p47phox translocation to the VSMC membrane 2-fold, an effect that was prevented by Mk2 knockdown (Figure 7A). Basal p47phox membrane/cytosolic ratio was not altered by Mk2 knockdown.
Ang II–Induced NADPH Oxidase Upregulates MK2 Expression

To determine whether activation of NADPH oxidase affects the expression of MK2, VSMCs were pretreated with the NADPH oxidase inhibitor Nox2ds-tat and then stimulated or not with Ang II. Nox2ds-tat is a small peptide that was designed to inhibit assembly of p47phox with gp91-phox (Nox2) and thus inhibit NADPH oxidase (Nox2) activation. An Ang II–induced increase of MK2 protein levels was prevented by ds-tat but not by the ds-tat scrambled peptide.

Figure 4. Downregulation of MK2 prevents Ang II–induced proinflammatory molecules. The protein levels of ICAM-1 (A), VCAM-1 (B), NF-κB p65 subunit (C), and Ets-1 (D) were determined in VSMCs transfected with siMK2 or with the luciferase siRNA (siLuc) used as a negative control and treated with vehicle (Veh) or Ang II for 24 hours. Representative Western blots of proinflammatory mediators and bar graphs representing proinflammatory molecule expression in different conditions are shown. Results are means ± SEM; n = 4 to 5; *P < 0.05 vs siLuc or Veh and †P < 0.05 vs siLuc + Ang II.

Figure 5. Downregulation of MK2 prevents Ang II–induced increase of MCP-1. The mRNA (A) and protein (B) levels of MCP-1 were determined in VSMCs transfected with siMK2 or with the luciferase siRNA (siLuc) used as a negative control and treated with vehicle (Veh) or Ang II for 24 hours. Results are means ± SEM; n = 4; *P < 0.05 vs siLuc + Veh and †P < 0.05 vs siLuc + Ang II.
This result suggests that Ang II–induced NADPH oxidase-driven superoxide generation induces a positive feedback loop by increasing the expression of MK2. Downregulation of MK2 Caused Ang II to Upregulate Catalase in VSMCs
We then evaluated the effects of modulation of MK2 on expression of the antioxidant catalase in VSMCs. Neither Ang II nor MK2 knockdown had any effect on the basal levels of catalase (Figure 8). However, in presence of siMK2, Ang II increased catalase expression by 53%. These results suggest that MK2 has an inhibitory effect on catalase in oxidative conditions, which further increases ROS production.

Downregulation of MK2 Prevents Ang II–Induced VSMC Proliferation
To determine whether MK2 mediates Ang II–induced vascular remodeling, VSMC proliferation was evaluated using [3H]thymidine incorporation. MK2 knockdown decreased by 50% [3H]thymidine VSMC incorporation under basal conditions (Figure 9). Ang II increased [3H]thymidine incorporation into VSMCs by 30%, which was abolished by MK2 knockdown, suggesting that MK2 is a mediator of Ang II–induced proliferation.

Discussion
The present study demonstrates the following novel findings. In vivo, Mk2 plays a key role in Ang II–induced rise in blood pressure and vascular superoxide production and inflammation. Similarly, in vitro, MK2, one of the direct downstream targets of p38 MAPK, mediates Ang II–induced increase of inflammatory mediators as well as superoxide production from NADPH oxidase, through regulation of the p47phox subunit of NADPH oxidase and the antioxidant enzyme catalase, and VSMC proliferation.

To investigate the role of MK2 in Ang II–induced hypertension, we performed in vivo experiments using Mk2 KO mice. There are contradictory results on the effect of p38 MAPK pharmacological inhibitors on hypertension in different conditions (Figure 9). Ang II increased [3H]thymidine incorporation into VSMCs by 30%, which was abolished by MK2 knockdown, suggesting that MK2 is a mediator of Ang II–induced proliferation.
MK2 and Vascular Inflammation

Downregulation of MK2 blocks Ang II–induced VSMC proliferation. [3H]thymidine incorporation was determined in VSMCs transfected with siMK2 or with the luciferase siRNA (siLuc) used as a negative control and treated with vehicle (Veh) or Ang II for 24 hours. Results are means±SEM; n=5; *P<0.05 vs siLuc or Veh and †P<0.05 vs siLuc+Ang II.

Figure 9. Downregulation of MK2 blocks Ang II–induced VSMC proliferation. [3H]thymidine incorporation was determined in VSMCs transfected with siMK2 or with the luciferase siRNA (siLuc) used as a negative control and treated with vehicle (Veh) or Ang II for 24 hours. Results are means±SEM; n=5; *P<0.05 vs siLuc or Veh and †P<0.05 vs siLuc+Ang II.

Figure 8. MK2 knockdown causes Ang II to upregulate catalase in VSMCs. Catalase protein levels were determined in VSMCs transfected with siMK2 or with the luciferase siRNA (siLuc) used as a negative control and treated with vehicle (Veh) or Ang II for 24 hours. Representative Western blots of catalase and bar graphs representing catalase expression in different conditions are presented. Results are means±SEM; n=6; *P<0.05 vs siLuc or Veh.

MK2 and Vascular Inflammation

Downregulation of MK2 blocks Ang II–induced VSMC proliferation. [3H]thymidine incorporation was determined in VSMCs transfected with siMK2 or with the luciferase siRNA (siLuc) used as a negative control and treated with vehicle (Veh) or Ang II for 24 hours. Results are means±SEM; n=5; *P<0.05 vs siLuc or Veh and †P<0.05 vs siLuc+Ang II.

Figure 9. Downregulation of MK2 blocks Ang II–induced VSMC proliferation. [3H]thymidine incorporation was determined in VSMCs transfected with siMK2 or with the luciferase siRNA (siLuc) used as a negative control and treated with vehicle (Veh) or Ang II for 24 hours. Results are means±SEM; n=5; *P<0.05 vs siLuc or Veh and †P<0.05 vs siLuc+Ang II.

Figure 8. MK2 knockdown causes Ang II to upregulate catalase in VSMCs. Catalase protein levels were determined in VSMCs transfected with siMK2 or with the luciferase siRNA (siLuc) used as a negative control and treated with vehicle (Veh) or Ang II for 24 hours. Representative Western blots of catalase and bar graphs representing catalase expression in different conditions are presented. Results are means±SEM; n=6; *P<0.05 vs siLuc or Veh.
Ang II induced a slight increase of catalase, a major antioxidant enzyme. Moreover, we found that only in the absence of MK2, the enzyme that is involved in the regulation of p47phox by MK2 could be upregulated. We have shown that MK2 plays a role in Ang II–induced cell growth. p38 MAPK is activated by G-protein–coupled receptors, such as Ang II type 1 receptors, and plays an important role in the induction of proliferative responses in susceptible cells. However, in rat VSMCs, Ang II–induced growth may be p38 MAPK independent. It was reported recently that endothelin-1 drives proliferation of VSMCs through stimulation of extracellular signal-regulated kinase and p38 MAPK. Moreover, very recently, using a cardiomyocyte-specific and inducible transgenic approach, MK2 activity was shown to play an important role in p38 MAPK–mediated cardiac hypertrophy and heart failure.

Our findings suggest that MK2 activation by Ang II may contribute to vascular remodeling by promoting cell growth.

In vivo data on blood pressure support clearly the implication of MK2 in Ang II–induced hypertension, and the potential molecular mechanism was demonstrated in VSMCs. However, additional in vivo experiments will be performed to confirm the proposed signaling pathway. Experiments with shorter time of Ang II infusion may be needed to determine whether the observed Ang II effects involving MK2 are related to blood pressure increase.

In summary, the data reported here demonstrate the novel findings that MK2 is involved in Ang II–induced hypertension and is upregulated by Ang II in VSMCs through generation of ROS via NADPH oxidase, likely Nox2 oxidase. Activation of MK2 upregulates proinflammatory molecules that further activate ROS generation, via effects on the p47phox subunit of NADPH oxidase as well as on antioxidant enzymes. Upregulation of MK2 appears to be part of a vicious circle that potentiates inflammatory responses to Ang II, leading as well to an increase in VSMC proliferation (Figure 10).

Perspectives
Clinical trials with p38 MAPK pharmacological inhibitors as anti-inflammatory therapies have been shown to be ineffective, attributable in part to the influence of p38 MAPK on diverse cellular pathways. The present results show for the first time that MK2 is an essential component of Ang II–induced hypertension and vascular oxidative stress and inflammation and could be a promising target for specific cardiovascular anti-inflammatory therapy.

Acknowledgments
We thank Dr Bruce G. Allen of the Montreal Heart Institute for the Mk2 KO breeder pair mice. We are also grateful to André Turgeon and Marie-Ève Deschénes for excellent technical support and animal care.
Sources of Funding
This work was funded by Canadian Institutes of Health Research (CIHR) grant MOP82790 to E.L.S., by Canada Research Chairs (CRC) from the CRC Government of Canada/CIHR Program and the Canada Fund for Innovation (CFI) to E.L.S. and S.W. T.E. was supported by a fellowship from the Heart and Stroke Foundation of Canada.

Disclosures
None.

References
7. Zhang GY, Li X, Yi CG, Pan H, He GD, Yu Q, Jiang LF, Xu WH, Li ZJ, Shen X. MK2 and Vascular Inflammation. 9. Ebrahimian et al. MK2 and Vascular Inflammation
References
9. Ebrahimian et al. MK2 and Vascular Inflammation


Mitogen-Activated Protein Kinase–Activated Protein Kinase 2 in Angiotensin II–Induced Inflammation and Hypertension. Regulation of Oxidative Stress
Talin Ebrahimian, Melissa Wei Li, Catherine A. Lemarié, Stefania M.C. Simeone, Patrick J. Pagano, Matthias Gaestel, Pierre Paradis, Sven Wassmann and Ernesto L. Schiffrin

_Hypertension_. published online December 20, 2010;
_Hypertension_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2010 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/early/2010/12/20/HYPERTENSIONAHA.110.159889.citation

Data Supplement (unedited) at:
http://hyper.ahajournals.org/content/suppl/2010/12/17/HYPERTENSIONAHA.110.159889.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Hypertension_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Hypertension_ is online at:
http://hyper.ahajournals.org//subscriptions/
Supplemental Material

MAP Kinase-Activated Protein Kinase 2 in Angiotensin II-induced Inflammation and Hypertension: Regulation of Oxidative Stress

Talin Ebrahimian¹, Melissa Wei Li¹, Catherine A. Lemarie¹, Stefania M.C. Simeone¹, Patrick J. Pagano³, Matthias Gaestel⁴, Pierre Paradis¹, Sven Wassmann¹,², Ernesto L. Schiffrin¹,²

¹Lady Davis Institute for Medical Research and ²Department of Medicine, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montréal, Québec, Canada; ³Department of Pharmacology & Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; ⁴Institute of Biochemistry, Medical School of Hannover, Germany.

Short Title: MK2 and Vascular Inflammation

Corresponding author: Ernesto L. Schiffrin, MD, PhD, FRSC, FRCPC

Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, 3755 Côte-Ste-Catherine Rd., #B-127, Montreal, PQ, Canada H3T 1E2
Ph: 514-340-7538
Fax: 514-340-7539
E-mail: ernesto.schiffrin@mcgill.ca
Methods

Nuclear extract preparation

VSMC nuclear extracts were prepared as previously described (1) with a minor modification. Nuclei were resuspended in 50 µl of ice cold lysis buffer and incubated on ice for 15 min. The suspension was centrifuged at 13000 rpm for 10 min. Protein concentration in the supernatant was determined using the Bradford method.

Western-Blotting

Total or fractioned proteins (15-20 µg) were extracted from VSMCs, separated by SDS-PAGE, transferred to nitrocellulose membranes and incubated overnight at 4°C with antibodies (1:1000) against the following: MK2, p38 MAPK and NF-κB p65 subunit from Cell Signaling Technology (Danvers, MA), and ICAM-1, VCAM-1, Ets-1 and p47phox from Santa Cruz Biotechnology (Santa Cruz, CA). After incubation with secondary antibodies, signals were revealed by chemiluminescence (SuperSignal West Pico chemiluminescent signal, Thermo scientific, Rockford, IL), with the Molecular Imager Chemidoc XRS system (Bio-Rad, Mississauga, ON, Canada), and quantified by densitometry using Quantity one software (Bio-Rad). Membranes were subsequently stripped and reprobed with anti-ß-actin antibody (Sigma Chemicals) to verify equal loading. VCAM-1 was also determined in protein extracts of mesenteric arteries stripped of fat from Mk2 KO and WT mice.

Quantitative RT-PCR

The following primers were used with an annealing temperature of 58°C. MCP-1, 5′-AGCTCTCTCTTCCACCAC-3′ (sense) and 5′-TCTGGACCCATTCCCTTGTG-3′ (antisense) and S16, 5′-TCTGGGCAAGGAGAGATTG-3′ (sense) and 5′-CCGCCAAACTTCTTGGATT-3′ (antisense).

Reactive oxygen species levels

Intracellular ROS levels were evaluated using 5-(and 6)-chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate, acetyl ester mixed isomers (CM-H₂DCFDA, Invitrogen). Briefly, VSMCs plated on black 96-well plate were transfected with siMK2 or siLuc, serum starved, treated or not with Nox2ds-tat and then stimulated with or without Ang II for 5 min as above. Then, cells were washed with phosphate-buffered saline, and incubated with CM-H₂DCFDA (10 µmol/L) for 30 minutes at room temperature and fluorescence red every 2 minutes for 60 minutes using a Fluoskan Ascent FL (Thermo Fischer Scientific Inc., Waltham, MA).

Dihydroethidium (DHE) was used to evaluate in situ production of superoxide (•O₂⁻)(2) in VSMCs and 10 µm-thick cryosections of aorta of WT and Mk2 KO. VSMCs were transfected for with siMK2 or siLuc, serum starved, stimulated with or without Ang II for 10 min as above and then incubated at 37°C with DHE (2 µmol/L) or vehicle for 30 min. Fluorescence was visualized with a DM2000 microscope with a CY3 filter (555 nm) (Leica Microsystems, Richmond Hill, ON, Canada). Frozen sections of aorta were incubated with DHE (100 µmol/L) for 5 min at room temperature and fluorescence determined as above.

NADPH oxidase activity

The lucigenin-enhanced chemiluminescence assay was used to determine NADPH oxidase activity in VSMC homogenates as previously described (3). VSMCs were transfected with
siMK2 or siLuc, serum starved and pre-exposed or not to Nox2ds-tat or its scrambled control and stimulated with or without Ang II for 5 min as above. Briefly, samples were homogenized in ROS lysis buffer. One hundred µL of homogenate was used for the lucigenin-based chemiluminescence assay in an Orion II microplate luminometer (Berthold detection systems GmbH, Pforzheim, Germany). Background was determined over 10 s, 100 µl of lucigenin (12.5 µmol/L) were injected and light measured for 1 s every ~6 s for 3 min. Then 50 µL of NADPH (0.5 mmol/L) were injected and light was measured for an additional 3 min as for lucigenin. NADPH oxidase activity was calculated by subtracting the results of luminescence before from after NADPH addition. Activity was corrected for protein concentration and expressed as % of negative control.

**Proliferation Assay**

Ang II-stimulated DNA synthesis was determined by measuring incorporation of [³H]thymidine into DNA. VSMCs were cultured in a 96 well-microplates. At 70-80 % confluency, cells were transfected with siMK2 or siLuc, serum starved and stimulated with or without Ang II or 10% fetal bovine serum for 24 h as above. During the last 6 hours of incubation, 1 µCi/ml of [³H]thymidine was added to the media. The medium was removed and the cells were washed with cold PBS. [³H]thymidine incorporation into DNA was assessed using a TopCount NXT scintillation counter (Perkin Elmer, Waltham, MA).
Reference List


